Clinical Trial Update: Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial evaluating metreleptin in children under 6 with generalized lipodystrophy; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Lipodystrophy

Drugs mentioned

• Metreleptin (metreleptin)

Snippet

Sponsor: Amryt Pharma | Conditions: Generalized Lipodystrophy | Phase 3 | Status: RECRUITING